Showing results (901-910 of 927) with videos related to

Sort By:
Pageof 93
Science China. Life Sciences|June 25, 2019
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young womenYue-Mei Hu, Meng Guo, Chang-Gui Li, et al.
JCI Insight|July 13, 2023
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase functionAnbarasu Kumaraswamy, Zhi Duan, Diana Flores, et al.
Lancet (London, England)|August 24, 2010
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialFeng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of an Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
A large-scale single-cell atlas reveals the pulmonary immune panorama in adult patients with influenzaKun Xiao, Yan Cao, Zhihai Han, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|December 29, 2020
Clinical characteristics and treatment outcome of COVID-19 patients with stroke in China: A multicenter retrospective studyXin-Yu Ji, Yan Ma, Nan-Nan Shi, et al.
The New England Journal of Medicine|March 5, 2015
Long-term efficacy of a hepatitis E vaccineJun Zhang, Xue-Feng Zhang, Shou-Jie Huang, et al.
Cancer Medicine|July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Cancer Medicine|December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Lancet (London, England)|January 29, 2013
Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trialFeng-Cai Zhu, Zheng-Lun Liang, Xiu-Ling Li, et al.
Pageof 93